Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label
tabling member	label

Search

58348

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Eyesight: Health Services
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the costs of a patient who presents with eye conditions as a first point of call (a) a GP, (b) a hospital eye service, (c) an accident and emergency department and (d) a primary eyecare acute referral scheme.
tabling member constituency	Plymouth, Moor View
tabling member printed	Alison Seabeck
uin	199248
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>The information is not available in the format requested. Such information as is available is shown in the following table.</p><p> </p><p>Estimated unit costs of a patient contact , 2012-13</p><p> </p><table><tbody><tr><td><p>Type of patient contact</p></td><td><p>Unit cost</p></td></tr><tr><td><p>General practitioner (GP) consultation<sup>1</sup></p></td><td><p>£37</p></td></tr><tr><td><p>First consultant-led appointment in an ophthalmology outpatient clinic<sup>2</sup></p></td><td><p>£108</p></td></tr><tr><td><p>Accident and emergency attendance<sup>3</sup></p></td><td><p>£130</p></td></tr><tr><td><p>Primary eyecare acute referral scheme</p></td><td><p>Not known</p></td></tr></tbody></table><p> </p><p><em>Notes:</em></p><p><sup>1</sup>The Department does not collect information on the unit cost of a GP consultation. An estimate of £37 per patient contact lasting 11.7 minutes, including direct care staff costs and excluding qualification costs, is included in page 198 of Unit Costs of Health and Social Care 2013 at www.pssru.ac.uk/project-pages/unit-costs/2013/. The data does not separately identify patients presenting with eye conditions or any other conditions.</p><p> </p><p><sup>2</sup>The average unit cost of first, face-to-face, consultant-led contacts in ophthalmology, medical ophthalmology and paediatric ophthalmology, weighted for activity. The information is from reference costs, which are the unit costs to NHS trusts and NHS foundation trusts of providing defined services in a given financial year to NHS patients, collected annually and published by the Department for 2012-13 at www.gov.uk/government/publications/nhs-reference-costs-2012-to-2013</p><p> </p><p><sup>3</sup>The average unit of cost of accident and emergency attendances from 2012-13 reference costs. Includes attendances resulting in and not resulting in an admission. Excludes attendances submitted against Healthcare Resource Groups (HRGs) for Emergency Medicine, Dental Care (VB10Z) and Emergency Medicine, No Investigation with No Significant Treatment (VB11Z). The data does not separately identify patients presenting with eye conditions or any other conditions.</p><p> </p><p><em>Sources:</em></p><p>2012/13 reference costs, Department of Health</p><p>Unit Costs of Health and Social Care 2013, Personal Social Services Research Unit</p><p> </p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 11/06/2014 15:43:52 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1552 label Biography information for Alison Seabeck

58391

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps he is taking to increase the amount of research undertaken into ways to detect the origin of primary cancer in those suffering from cancer of the unknown primary.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199372
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>Research infrastructure funded by the Department's National Institute for Health Research (NIHR) is currently hosting the following study:</p><p> </p><p>A multi-centre phase II trial to assess the efficacy of epirubicin, cisplatin and capecitabine in carcinomas of unknown primary: incorporating the prospective validation of molecular classifiers in diagnosis and classification and exploratory metabonomics.</p><p> </p><p>Overall NIHR investment in cancer research increased from £102 million in 2009-10 to £133 million in 2012-13. The NIHR welcomes funding applications for research into any aspect of human health, including cancer of unknown primary. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and the National Health Service, value for money and scientific quality.</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 11/06/2014 15:28:17 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	4036 label Biography information for Luciana Berger

58392

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Sunbeds
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, whether the Government plans to respond to the recommendations set out in the report of the All Party Parliamentary Group on Skin on sunbed regulation published in 2014.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199381
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The Government has noted the report and is currently considering how to respond to the recommendations<strong>.</strong></p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 15:23:48 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58393

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Human Papillomavirus
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what estimate he has made of the potential cost of extending the human papilloma virus vaccination programme to include all boys aged 12 and 13 years.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199382
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>We have not made any estimate of extending the human papillomavirus (HPV) vaccination programme to include boys aged 12 and 13 years, as the Joint Committee on Vaccination and Immunisation has not yet completed its consideration of whether HPV vaccine should be offered to males.</p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 14:44:56 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58394

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Pregnancy: Alcoholic Drinks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the Government's assessment is of the effectiveness of warning labels on alcoholic beverages regarding drinking during pregnancy; and what assessment he has made of the potential benefits of making such labels mandatory.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199389
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>Research in the evidence around the effectiveness of alcohol harm reduction communications and related campaigns suggests that labelling and point of sale information can have an impact on consumption, in conjunction with broader campaigns to raise consumer awareness and education on the health risks linked to alcohol consumption.</p><p><strong> </strong></p><p>As part of the Public Health Responsibility Deal, alcohol retailers and producers have committed to putting an agreed warning or a pregnancy warning logo on 80% of labels on bottles and cans by the end of 2013. An independent market survey is underway to measure compliance. This level of coverage should allow the majority of consumers to see the pregnancy warning and logo.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison question first answered 10/06/2014 15:29:37 answering member 3918 label Biography information for Jane Ellison
tabling member	4036 label Biography information for Luciana Berger

58395

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Academic Health Science Networks
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what the running costs for each of the academic health science networks are.
tabling member constituency	Liverpool, Wavertree
tabling member printed	Luciana Berger
uin	199345
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The information requested is not available.</p><p> </p><p>NHS England advises us that individual funding levels and programme costs vary between Academic Health Science Networks (AHSNs). NHS England budget allocations are not their sole source of income and AHSNs are seeking to supplement this funding through participation in strategic investment programmes and match-funding initiatives. Core running costs are for AHSNs to determine independently and may also be subject to change through the year.</p><p> </p><p>Further information on AHSN work programmes and business plans can be found on their websites:</p><p> </p><table><tbody><tr><td><p>AHSN</p></td><td><p>Website</p></td></tr><tr><td><p>East Midlands</p></td><td><p><a href="http://www.emahsn.ac.uk/" target="_blank">www.emahsn.ac.uk</a></p></td></tr><tr><td><p>Eastern</p></td><td><p><a href="http://www.eahsn.org.uk/" target="_blank">www.eahsn.org.uk</a></p></td></tr><tr><td><p>Imperial College Health Partners</p></td><td><p><a href="http://www.imperialcollegehealthpartners.com/" target="_blank">www.imperialcollegehealthpartners.com</a></p></td></tr><tr><td><p>Greater Manchester</p></td><td><p><a href="http://www.gmahsn.org/" target="_blank">www.gmahsn.org</a></p></td></tr><tr><td><p>Kent, Surrey and Sussex</p></td><td><p><a href="http://www.kssahsn.net/" target="_blank">www.kssahsn.net</a></p></td></tr><tr><td><p>North East and North Cumbria</p></td><td><p><a href="http://www.ahsn-nenc.org.uk/" target="_blank">www.ahsn-nenc.org.uk</a></p></td></tr><tr><td><p>North West Coast</p></td><td><p><a href="http://www.nwcahsn.nhs.uk/" target="_blank">www.nwcahsn.nhs.uk</a></p></td></tr><tr><td><p>Oxford</p></td><td><p><a href="http://www.oxfordahsn.org/" target="_blank">www.oxfordahsn.org</a></p></td></tr><tr><td><p>South London</p></td><td><p><a href="http://www.kingshealthpartners.org/info/southlondonahsn" target="_blank">www.kingshealthpartners.org/info/southlondonahsn</a></p></td></tr><tr><td><p>South West Peninsula</p></td><td><p><a href="http://www.swahsn.com/" target="_blank">www.swahsn.com</a></p></td></tr><tr><td><p>UCL Partners</p></td><td><p><a href="http://www.uclpartners.com/" target="_blank">www.uclpartners.com</a></p></td></tr><tr><td><p>Wessex</p></td><td><p><a href="http://www.wessexahsn.org/" target="_blank">www.wessexahsn.org</a></p></td></tr><tr><td><p>West Midlands</p></td><td><p><a href="http://www.wmahsn.org/" target="_blank">www.wmahsn.org</a></p></td></tr><tr><td><p>West of England</p></td><td><p><a href="http://www.weahsn.net/" target="_blank">www.weahsn.net</a></p></td></tr><tr><td><p>Yorkshire and Humber</p></td><td><p><a href="http://www.yhahsn.org.uk/" target="_blank">www.yhahsn.org.uk</a></p></td></tr></tbody></table><p> </p><p> </p><p> </p><p> </p> answering member constituency North Norfolk answering member printed Norman Lamb question first answered 10/06/2014 14:27:05 answering member 1439 label Biography information for Norman Lamb
tabling member	4036 label Biography information for Luciana Berger

58397

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Bone Diseases: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what steps his Department is taking to maintain and improve specialist services for children suffering from brittle bone disease.
tabling member constituency	Upper Bann
tabling member printed	David Simpson
uin	199226
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>The nature of brittle bone disease requires care across the healthcare system, the majority being provided in the community by a variety of therapists with involvement from a wide multi-disciplinary team. The provision of services for children with brittle bone disease in Northern Ireland will be a matter for the Northern Ireland Executive and the health service in Northern Ireland.</p><p> </p><p>In England, in the majority of cases the local clinical commissioning group (CCG) will decide on the level of provision of services, taking into account the needs of the population it serves. The CCG's decisions are underpinned by clinical insight and knowledge of local healthcare needs.</p><p> </p><p>Complex childhood brittle bone services in England are commissioned by NHS England which has developed a specification for these services. This can be found at:</p><p> </p><p>www.england.nhs.uk/wp-content/uploads/2013/06/e13-child-osteo-imperfecta.pdf</p><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 11/06/2014 15:23:02 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	1597 label Biography information for David Simpson

58426

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Dental Health: Children
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the trends in the incidence of dental caries among school children (a) in Bolton and (b) nationally since 2010.
tabling member constituency	Bolton North East
tabling member printed	Mr David Crausby
uin	199206
answer	answer is ministerial correction date of answer 11/06/2014 answer text <p>There has been only one published survey of dental caries among schoolchildren which includes the Bolton area since 2010. This is the <em>National Dental Epidemiology Programme for England: oral health survey of five-year-old children 2012, A report on the prevalence and severity of dental decay</em>. This can be found at the following link:</p><p> </p><p>www.nwph.net/dentalhealth/survey-results5.aspx?id=1</p><p> </p><p>A comparison of selected findings from the survey, and from the previous survey of five year old children in England, published in 2009, the <em>NHS Dental Epidemiology Programme for England, Oral Health Survey of 5 year old Children, 2007/2008</em> can be found at the following link:</p><p> </p><p>www.nwph.info/dentalhealth/survey-results.aspx?id=1</p><p> </p><p>The comparisons are supplied in the following table:</p><p> </p><table><tbody><tr><td><p>Bolton Local Authority area</p></td><td><p>2008</p></td><td><p>2012</p></td></tr><tr><td><p>Number of children examined</p></td><td><p>298</p></td><td><p>262</p></td></tr><tr><td><p>Mean number decayed, missing or filled teeth (dmft)</p></td><td><p>1.91</p></td><td><p>1.85</p></td></tr><tr><td><p>Proportion of children with lifetimes caries experience (% dmft&gt;0)</p></td><td><p>46.3%</p></td><td><p>43.4%</p></td></tr></tbody></table><p> </p><table><tbody><tr><td><p>National (England)</p></td><td><p>2008</p></td><td><p>2012</p></td></tr><tr><td><p>Number of children examined</p></td><td><p>139,727</p></td><td><p>133,516</p></td></tr><tr><td><p>Mean number decayed, missing or filled teeth (dmft)</p></td><td><p>1.11</p></td><td><p>0.94</p></td></tr><tr><td><p>Proportion of children with lifetimes caries experience (% dmft&gt;0)</p></td><td><p>30.9%</p></td><td><p>27.9%</p></td></tr></tbody></table><p> </p> answering member constituency Central Suffolk and North Ipswich answering member printed Dr Daniel Poulter question first answered 11/06/2014 15:46:49 answering member 3932 label Biography information for Dr Dan Poulter
tabling member	437 label Biography information for Sir David Crausby

58513

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what assessment he has made of the changes in the level of access to prostate cancer treatments since 2010.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199302
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199303 199304 question first answered 10/06/2014 15:28:08 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile

58515

registered interest
date	05/06/2014
answering body	Department of Health
answering dept id	17
answering dept short name	Health
answering dept sort name	Health
hansard heading	Prostate Cancer
house id	1
legislature	25259 pref label House of Commons
question text	To ask the Secretary of State for Health, what treatments for prostate cancer are routinely funded by NHS England.
tabling member constituency	Plymouth, Sutton and Devonport
tabling member printed	Oliver Colvile
uin	199303
answer	answer is ministerial correction date of answer 10/06/2014 answer text <p>The NHS England Specialised Commissioning team introduced nationally developed service specifications for a range of areas, including prostate cancer, during 2013-14. Prior to 2013, prostate cancer was routinely commissioned by primary care trusts, and as such an assessment of the changes in the level of access to prostate cancer treatments since 2010 is not technically feasible.</p><p> </p><p>Routinely commissioned treatments for prostate cancer are: (i) radical prostatectomy; (ii) radical external beam radiotherapy; and (iii) radical brachytherapy. In addition, NHS England routinely commissions systemic treatments for prostate cancer, including hormone therapy and chemotherapy.</p><p> </p><p>The National Institute for Health and Care Excellence (NICE) has published technology appraisal guidance which recommends docetaxel (Taxotere) for hormone-refractory prostate cancer and abiraterone (Zytiga), in combination with prednisolone or prednisone, for castration-resistant metastatic prostate cancer previously treated with one docetaxel-containing regimen. NICE is also currently developing technology appraisal guidance on a number of other drugs for prostate cancer.</p><p> </p><p>National Health Service commissioners are legally required by regulations to fund those treatments recommended by NICE in its technology appraisal guidance.</p><p> </p><p>Five-year survival rates improved from around 42% in the late 1980s to 79.7% in 2007 (currently 80.2% according to data for 2006-2010 published in October 2012) due in part to the effects of increased Prostate Specific Antigen testing and earlier detection. However, survival rates in England are still lagging behind comparable countries in Europe.</p><p> </p><p>Cancer Research UK has estimated that men with advanced, incurable prostate cancer treated in trials or under drug access schemes at the Royal Marsden Hospital survived on average 41 months, compared to between 13 and 16 months 10 years ago.</p><p> </p><p>The Government's Mandate to NHS England sets out an ambition to make England one of the most successful countries in Europe at preventing premature deaths from all cancers, including prostate cancer. Cancer indicators in the NHS Outcomes Framework and the Public Health Outcomes Framework will help NHS England to assess progress in improving cancer survival and mortality for men with prostate cancer.</p><p> </p> answering member constituency Battersea answering member printed Jane Ellison grouped question UIN 199302 199304 question first answered 10/06/2014 15:28:10 answering member 3918 label Biography information for Jane Ellison
tabling member	4022 label Biography information for Oliver Colvile